Evaluation of Safety and Efficacy of TOCOSOL(R) Paclitaxel as Initial Treatment for Metastatic Breast Cancer
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
This is an open label study where each patient will receive TOCOSOL(R) Paclitaxel 120mg/m2
every week for first line treatment of metastatic breast cancer. Patients will be followed to
determine the efficacy of treatment (as measured by objective response rate), and the safety
associated with weekly administration of TOCOSOL Paclitaxel.